All In Biotech

Drug Trial Radar · NCT02446990

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease

Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 19,102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

19,102

Actual

Start

Sep 2009

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.

Conditions

  • Coronary Artery Disease

Interventions

  • IvabradineDrug

    5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.

  • PlaceboDrug

    Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Composite EndpointTime frame: The events are expressed as the time to occurrence of the first event, defined as the duration between the date of randomisation and the date of first occurrence of event, assessed up to 48 months.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Azienda Ospedaliera Universitaria di Ferrara

    Ferrara, Italy

  • Royal Brompton Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.